Trogarzo

RSS

Withdrawn

This medicine's authorisation has been withdrawn

ibalizumab
MedicineHumanWithdrawn

Maltese is available via eTranslation, the European Commission's machine translation service.

Translate to Maltese | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 1 January 2023, the European Commission withdrew the marketing authorisation for Trogarzo (ibalizumab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Theratechnologies Europe Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Trogarzo was granted marketing authorisation in the EU on 26 September 2019 for the treatment of adults infected with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive antiviral regimen. The marketing authorisation was initially valid for a 5-year period. 

The European Public Assessment Report (EPAR) for Trogarzo is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (729.99 KB - PDF)

Ara

español (ES) (657.7 KB - PDF)

Ara

čeština (CS) (716.14 KB - PDF)

Ara

dansk (DA) (656.3 KB - PDF)

Ara

Deutsch (DE) (663.12 KB - PDF)

Ara

eesti (ET) (73.34 KB - PDF)

Ara

ελληνικά (EL) (763.57 KB - PDF)

Ara

français (FR) (662.39 KB - PDF)

Ara

hrvatski (HR) (679.34 KB - PDF)

Ara

italiano (IT) (656.3 KB - PDF)

Ara

latviešu (LV) (716.2 KB - PDF)

Ara

lietuvių (LT) (680.41 KB - PDF)

Ara

magyar (HU) (728.36 KB - PDF)

Ara

Malti (MT) (724.22 KB - PDF)

Ara

Nederlands (NL) (657.17 KB - PDF)

Ara

polski (PL) (714.21 KB - PDF)

Ara

português (PT) (660.99 KB - PDF)

Ara

română (RO) (681.06 KB - PDF)

Ara

slovenčina (SK) (715.17 KB - PDF)

Ara

slovenščina (SL) (708.72 KB - PDF)

Ara

suomi (FI) (656.28 KB - PDF)

Ara

svenska (SV) (656.95 KB - PDF)

Ara

Product information

български (BG) (1.74 MB - PDF)

Ara

español (ES) (1.16 MB - PDF)

Ara

čeština (CS) (1.6 MB - PDF)

Ara

dansk (DA) (997.86 KB - PDF)

Ara

Deutsch (DE) (1.02 MB - PDF)

Ara

eesti (ET) (301.99 KB - PDF)

Ara

ελληνικά (EL) (1.68 MB - PDF)

Ara

français (FR) (1014.56 KB - PDF)

Ara

hrvatski (HR) (1.05 MB - PDF)

Ara

italiano (IT) (1.01 MB - PDF)

Ara

latviešu (LV) (1.54 MB - PDF)

Ara

lietuvių (LT) (1.1 MB - PDF)

Ara

magyar (HU) (1.49 MB - PDF)

Ara

Malti (MT) (1.52 MB - PDF)

Ara

Nederlands (NL) (1.01 MB - PDF)

Ara

polski (PL) (1.42 MB - PDF)

Ara

português (PT) (1 MB - PDF)

Ara

română (RO) (1.1 MB - PDF)

Ara

slovenčina (SK) (1.43 MB - PDF)

Ara

slovenščina (SL) (1.37 MB - PDF)

Ara

suomi (FI) (1017 KB - PDF)

Ara

svenska (SV) (960.21 KB - PDF)

Ara

Íslenska (IS) (922.11 KB - PDF)

Ara

norsk (NO) (1.03 MB - PDF)

Ara
Latest procedure affecting product information:IAIN/0020
12/10/2022
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (624.09 KB - PDF)

Ara

español (ES) (580.88 KB - PDF)

Ara

čeština (CS) (612.33 KB - PDF)

Ara

dansk (DA) (580.45 KB - PDF)

Ara

Deutsch (DE) (580.84 KB - PDF)

Ara

eesti (ET) (9.68 KB - PDF)

Ara

ελληνικά (EL) (623.37 KB - PDF)

Ara

français (FR) (580.53 KB - PDF)

Ara

hrvatski (HR) (595.43 KB - PDF)

Ara

italiano (IT) (580.88 KB - PDF)

Ara

latviešu (LV) (616.44 KB - PDF)

Ara

lietuvių (LT) (595.46 KB - PDF)

Ara

magyar (HU) (602.71 KB - PDF)

Ara

Malti (MT) (614.78 KB - PDF)

Ara

Nederlands (NL) (580.63 KB - PDF)

Ara

polski (PL) (613.79 KB - PDF)

Ara

português (PT) (580.71 KB - PDF)

Ara

română (RO) (597.59 KB - PDF)

Ara

slovenčina (SK) (611.37 KB - PDF)

Ara

slovenščina (SL) (602.75 KB - PDF)

Ara

suomi (FI) (580.44 KB - PDF)

Ara

svenska (SV) (580.68 KB - PDF)

Ara

Íslenska (IS) (599.47 KB - PDF)

Ara

norsk (NO) (600.04 KB - PDF)

Ara

Product details

Name of medicine
Trogarzo
Active substance
Ibalizumab
International non-proprietary name (INN) or common name
ibalizumab
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
J05AX

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Trogarzo, in combination with other antiretroviral(s), is indicated for the treatment of adults infected with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive antiviral regimen.

Authorisation details

EMA product number
EMEA/H/C/004961
Marketing authorisation holder
Theratechnologies Europe Limited

4th Floor
2 Hume Street
Dublin 2
D02 DV24
Ireland

Opinion adopted
25/07/2019
Marketing authorisation issued
26/09/2019
Withdrawal of marketing authorisation
01/01/2023
Revision
7

Assessment history

This page was last updated on

Share this page